SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples.
COVID-19
SARS-CoV-2
cohort
infectiousness
subgenomic RNA
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
05
2021
accepted:
09
06
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
Given the persistence of viral RNA in clinically recovered coronavirus disease 2019 (COVID-19) patients, subgenomic RNAs (sgRNAs) have been reported as potential molecular viability markers for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, few data are available on their longitudinal kinetics, compared with genomic RNA (gRNA), in clinical samples. We analyzed 536 samples from 205 patients with COVID-19 from placebo-controlled, outpatient trials of peginterferon Lambda-1a (Lambda; n = 177) and favipiravir (n = 359). Nasal swabs were collected at 3 time points in the Lambda (days 1, 4, and 6) and favipiravir (days 1, 5, and 10) trials. N-gene gRNA and sgRNA were quantified by quantitative reverse transcription polymerase chain reaction. To investigate the decay kinetics in vitro, we measured gRNA and sgRNA in A549 At 6 days in the Lambda trial and 10 days in the favipiravir trial, sgRNA remained detectable in 51.6% (32/62) and 49.5% (51/106) of the samples, respectively. Cycle threshold (Ct) values for gRNA and sgRNA were highly linearly correlated (marginal In clinical samples and in vitro, sgRNA was highly correlated with gRNA and did not demonstrate different decay patterns to support its application as a viability marker.
Sections du résumé
BACKGROUND
BACKGROUND
Given the persistence of viral RNA in clinically recovered coronavirus disease 2019 (COVID-19) patients, subgenomic RNAs (sgRNAs) have been reported as potential molecular viability markers for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, few data are available on their longitudinal kinetics, compared with genomic RNA (gRNA), in clinical samples.
METHODS
METHODS
We analyzed 536 samples from 205 patients with COVID-19 from placebo-controlled, outpatient trials of peginterferon Lambda-1a (Lambda; n = 177) and favipiravir (n = 359). Nasal swabs were collected at 3 time points in the Lambda (days 1, 4, and 6) and favipiravir (days 1, 5, and 10) trials. N-gene gRNA and sgRNA were quantified by quantitative reverse transcription polymerase chain reaction. To investigate the decay kinetics in vitro, we measured gRNA and sgRNA in A549
RESULTS
RESULTS
At 6 days in the Lambda trial and 10 days in the favipiravir trial, sgRNA remained detectable in 51.6% (32/62) and 49.5% (51/106) of the samples, respectively. Cycle threshold (Ct) values for gRNA and sgRNA were highly linearly correlated (marginal
CONCLUSIONS
CONCLUSIONS
In clinical samples and in vitro, sgRNA was highly correlated with gRNA and did not demonstrate different decay patterns to support its application as a viability marker.
Identifiants
pubmed: 34295944
doi: 10.1093/ofid/ofab310
pii: ofab310
pmc: PMC8291522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab310Subventions
Organisme : NIGMS NIH HHS
ID : R25 GM086262
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150741
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Nat Med. 2020 Jun;26(6):861-868
pubmed: 32327757
Emerg Infect Dis. 2021 Feb;27(2):632-635
pubmed: 33496233
BMC Med. 2020 Nov 4;18(1):346
pubmed: 33143712
J Virol. 2021 Feb 23;:
pubmed: 33622961
Future Microbiol. 2009 Feb;4(1):45-64
pubmed: 19207099
Food Environ Virol. 2009 Dec;1(3-4):123-128
pubmed: 20234879
PLoS Biol. 2020 Jun 8;18(6):e3000715
pubmed: 32511245
Annu Rev Virol. 2015 Nov;2(1):265-88
pubmed: 26958916
Retrovirology. 2018 Jan 17;15(1):9
pubmed: 29343255
J Virol. 2003 Jul;77(14):7890-902
pubmed: 12829829
Nat Commun. 2021 Mar 30;12(1):1967
pubmed: 33785743
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Nat Struct Mol Biol. 2021 Mar;28(3):319-325
pubmed: 33674802
Nat Commun. 2020 Nov 18;11(1):5885
pubmed: 33208793
Med J Armed Forces India. 2020 Oct;76(4):370-376
pubmed: 32895599
Science. 2020 Sep 11;369(6509):1395-1398
pubmed: 32763915
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
N Engl J Med. 2021 Feb 18;384(7):671-673
pubmed: 33503337
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):
pubmed: 33526596
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10157-E10166
pubmed: 30297408
Prehosp Disaster Med. 2020 Aug;35(4):470-471
pubmed: 32434624
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
Biochim Biophys Acta. 1960 Jul 29;42:99-116
pubmed: 13728193
FEMS Microbiol Lett. 2009 Feb;291(2):137-42
pubmed: 19054073
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12257-62
pubmed: 20562343
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Emerg Infect Dis. 2020 Nov;26(11):2701-2704
pubmed: 32749957
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447